Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631142 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL5631151 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| Trifluoroacetic Acid SCHEMBL5632440 | 0.88 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| Trifluoroacetic Acid SCHEMBL5632043 | 0.88 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL5632800 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL30309502 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL5631902 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL5631907 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 | |
| SCHEMBL28168047 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL7149297 | 0.84 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3CYP2D6ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | SLC6A2 60/4885SLC6A4 56/4885SLC6A3 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.